Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.87 |
| ▸ | ABL1 | P00519 | 2/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.57 |
| ▸ | SRC | P12931 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31004070 | 0.93 | EGFR (1.00) | EGFR | |
| SCHEMBL29363644 | 0.93 | EGFR (1.00) | EGFR | |
| SCHEMBL20865211 | 0.93 | EGFR (1.00) | EGFR | |
| SCHEMBL24329439 | 0.91 | EGFR (0.91) | EGFRABL1FGFR1SRC | |
| SCHEMBL20865221 | 0.86 | EGFR (0.87) | EGFRABL1PDGFRBFGFR1SRC | |
| SCHEMBL31538954 | 0.86 | EGFR (0.87) | EGFRABL1PDGFRBFGFR1SRC | |
| SCHEMBL20865335 | 0.85 | EGFR (0.74) | EGFR | |
| SCHEMBL20865232 | 0.85 | EGFR (0.74) | EGFR | |
| SCHEMBL24328554 | 0.84 | EGFR (0.72) | EGFRKDR | |
| SCHEMBL20856929 | 0.84 | EGFR (0.72) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215808-B | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2025-04-18 | — | — | CN | disclosed |
| US-20240058340-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | ERASCA, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | disclosed |
| US-11377451-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2022061202-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377451-B2 | Compositions and methods for treating cancer | TP53, EGFR, SLC2A1 | EGFR 2/4885ABL1 242/4885PDGFRB 285/4885 |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | EGFR 2/4885ABL1 284/4885PDGFRB 306/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | EGFR 3/4885ABL1 302/4885PDGFRB 403/4885 |
| US-20240058340-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | EGFR 2/4885ABL1 284/4885PDGFRB 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.